Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Pathology

Internal Medicine

Hematology

Surgery

Show all topics

DOI

10.1016/s1470-2045(15)00362-9

License

publisher-specific-oa